Subscribe

Coya Therapeutics, Inc. (COYA)

USD4.86 -0.01 (-0.20%)
US NASDAQ Healthcare Biotechnology
Address 5850 San Felipe Street 77057
Houston, TX, US
CEO Arun Swaminathan
Website coyatherapeutics.com
IPO 2022-12-29
CIK 1835022 ISIN US22407B1089

Explore sections of this company profile

Description

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD4.86 -0.01 (-0.20%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
170.0K
Beta
0.62
Float Shares
17.83M
Free Float %
106.6%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+5.83% +7.33% +2.02% -3.61% -23.83% -21.72% -21.18% -14.34% -0.66% -0.66% -0.66%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (5 ratings, all time) Buy
Price Targets & DCF
Current price
4.86
Low 17.00 +249.8%
Consensus 17.50 +260.1%
Median 17.50 +260.1%
High 18.00 +270.4%
DCF (Unlevered) 5.08 +4.4%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 7 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Price Target Summary
Period # Analysts Avg Target
Last Month — —
Last Quarter — —
Last Year 1
17.00
+249.8%
All Time 2
17.50
+260.1%
Quality scores
Altman Z-Score
-1.16
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +123.6% ★ Q1'26: +97,287.6% (vs Q1'25)
  • ✗
    EPS growth Biotechnology: +29.7%
    -29.6% Q1'26: +27.3% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -205.9% Q1'26: -2.5% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -255.1% Q1'26: +0.0% (vs Q1'25)
  • ✓
    ROIC Biotechnology: -16.1%
    — Q1'26: +0.0% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +9.8% Q1'26: +35.4% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.55) × ERP
WACC = 100% × Ke + 0% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 5.08 Current price: 4.86
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
5 Rev. Ana.
4 EPS Ana. 		Dec 2027
4 Rev. Ana.
2 EPS Ana. 		Dec 2028
3 Rev. Ana.
3 EPS Ana. 		Dec 2029
2 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
6.00M
est: 9.55M (-37.2%)
3.55M
est: 3.67M (-3.1%)
7.95M
est: 5.92M (+34.3%)
2.28M
2.28M – 2.28M
-61.5% YoY
7.46M
7.36M – 7.57M
+227.5% YoY
21.37M
21.37M – 21.37M
+186.3% YoY
13.00M
13.00M – 13.00M
-39.2% YoY
18.49M
18.49M – 18.49M
+42.2% YoY
EBITDA
-7.33M
est: -1.91M (-283.7%)
-17.20M
est: -733.5K (-2,244.7%)
-20.24M
est: -1.18M (-1,610.3%)
-455.7K
-455.7K – -455.7K
+61.5% YoY
-1.49M
-1.51M – -1.47M
-227.5% YoY
-4.27M
-4.27M – -4.27M
-186.3% YoY
-2.60M
-2.60M – -2.60M
+39.2% YoY
-3.70M
-3.70M – -3.70M
-42.2% YoY
EBIT
-7.36M
est: -1.91M (-285.2%)
-17.22M
est: -733.5K (-2,248.4%)
-20.27M
est: -1.18M (-1,612.6%)
-455.7K
-455.7K – -455.7K
+61.5% YoY
-1.49M
-1.51M – -1.47M
-227.5% YoY
-4.27M
-4.27M – -4.27M
-186.3% YoY
-2.60M
-2.60M – -2.60M
+39.2% YoY
-3.70M
-3.70M – -3.70M
-42.2% YoY
Net Income
-7.99M
est: -13.42M (+40.5%)
-14.88M
est: -18.32M (+18.8%)
-21.23M
est: -21.23M (+0.0%)
-23.30M
-25.49M – -21.11M
-9.8% YoY
-20.16M
-20.16M – -20.16M
+13.5% YoY
-14.74M
-34.80M – -2.51M
+26.9% YoY
-21.83M
-21.83M – -21.83M
-48.1% YoY
-19.74M
-19.74M – -19.74M
+9.6% YoY
SGA
7.83M
est: 13.85M (-43.4%)
8.89M
est: 5.31M (+67.2%)
11.45M
est: 8.57M (+33.5%)
3.30M
3.30M – 3.30M
-61.5% YoY
10.81M
10.66M – 10.97M
+227.5% YoY
30.97M
30.97M – 30.97M
+186.3% YoY
18.84M
18.84M – 18.84M
-39.2% YoY
26.79M
26.79M – 26.79M
+42.2% YoY
EPS
-0.79
est: -0.80 (+1.5%)
-0.98
est: -1.09 (+10.5%)
-1.27
est: -1.19 (-6.4%)
-1.39
-1.52 – -1.26
-16.7% YoY
-1.21
-1.21 – -1.21
+13.5% YoY
-0.81
-2.08 – -0.15
+32.5% YoY
-1.31
-1.31 – -1.31
-60.5% YoY
-1.18
-1.18 – -1.18
+9.6% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-11 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-08 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-07 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-06 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-05 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-04 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-05-01 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-30 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-29 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-28 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-27 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-24 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-23 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-22 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-21 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-20 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-17 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5
2026-04-16 C- 1/5 1/5 1/5 1/5 1/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-11.43B
OE per share TTM
-683.14
Owner's Yield
-16,343.00%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1.9%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
9
Total invested
4.24M
Insider transactions (90d)
0
Beneficial owners (>5%)
9
Beneficial owners (>5%)
# Reporting person ⇅ Amount owned ⇅ % of class ⇅ Sole voting ⇅ Shared voting ⇅ Sole dispositive ⇅ Shared dispositive ⇅ Type Citizenship Filing date ⇅ SEC filing
1 David Einhorn 1.28M 8.90% — 1.28M — 1.28M HC U.S. Citizen 2023-12-12 ↗
2 Bertex LLC 939.3K 14.20% 939.3K — 939.3K — OO — 2023-02-14 ↗
3 Howard Berman 939.3K 14.20% 939.3K — 939.3K — IN — 2023-02-14 ↗
4 DME Advisors GP, LLC 837.0K 5.80% — 837.0K — 837.0K HC Delaware 2023-12-12 ↗
5 Identification Nos. of above persons (. 692.4K 7.20% 692.4K — 692.4K — IN States 2023-01-05 ↗
6 DME Capital Management, LP 597.9K 4.20% — 597.9K — 597.9K IA Delaware 2023-12-12 ↗
7 27-4413262 560.0K 5.80% 560.0K — 560.0K — OO Maryland 2023-01-05 ↗
8 Greenlight Capital, Inc. 442.0K 3.10% — 442.0K — 442.0K IA Delaware 2023-12-12 ↗
9 DME Advisors, LP 239.1K 1.70% — 239.1K — 239.1K IA Delaware 2023-12-12 ↗

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2026 Q1
Investors holding
9
-49 vs prev Q
New positions
2
Closed positions
51
Increased
5
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
# Investor ⇅ Shares / Δ ⇅ Mkt value / Δ ⇅ Own% / Δ ⇅ Weight% / Δ ⇅ Avg px / Perf. ⇅ Hold / Status ⇅
1 DME CAPITAL MANAGEMENT, LP 2.03M +379.5K (+23.0%) 11.75M +2.4M (+25.2%) 12.11% +2.263 pp 0.41% +0.043 pp USD8.30 -30.1% 8 qtrs —
2 AIGH CAPITAL MANAGEMENT LLC 975.4K -130.2K (-11.8%) 5.66M -644.7K (-10.2%) 5.83% -0.781 pp 1.37% -0.407 pp USD5.88 -1.4% 13 qtrs —
3 VANGUARD GROUP INC 899.1K +62.7K (+7.5%) 5.22M +447.6K (+9.4%) 5.37% +0.373 pp 0.00% +0.000 pp USD9.21 -37.0% 10 qtrs —
4 ALYESKA INVESTMENT GROUP, L.P. 800.0K +800.0K (+100.0%) 4.64M +4.6M (+100.0%) 4.78% +4.781 pp 0.01% +0.013 pp USD5.80 +0.0% 1 qtrs NEW
5 AWM INVESTMENT COMPANY, INC. 725.0K +725.0K (+100.0%) 4.21M +4.2M (+100.0%) 4.33% +4.333 pp 0.41% +0.406 pp USD5.80 +0.0% 1 qtrs NEW
6 CM MANAGEMENT, LLC 350.0K +50.0K (+16.7%) 2.03M +320.0K (+18.7%) 2.09% +0.298 pp 1.71% +0.286 pp USD5.41 +7.2% 11 qtrs —
7 PRIVATE MANAGEMENT GROUP INC 280.3K +280.3K (+100.0%) 1.63M +1.6M (+100.0%) 1.68% +1.675 pp 0.05% +0.047 pp USD5.80 +0.0% 1 qtrs NEW
8 MARSHALL WACE, LLP 225.4K +183.5K (+438.8%) 1.31M +1.1M (+448.3%) 1.35% +1.097 pp 0.00% +0.001 pp USD5.78 +0.3% 2 qtrs —
9 GEODE CAPITAL MANAGEMENT, LLC 198.0K +41.1K (+26.2%) 1.15M +254.3K (+28.4%) 1.18% +0.245 pp 0.00% +0.000 pp USD5.77 +0.5% 11 qtrs —
10 SUSQUEHANNA INTERNATIONAL GROUP, LLP 124.8K +91.5K (+274.2%) 724.0K +533.9K (+280.8%) 0.75% +0.547 pp 0.00% +0.000 pp USD5.88 -1.4% 5 qtrs —
11 JBF CAPITAL, INC. 100.0K +100.0K (+100.0%) 580.0K +580.0K (+100.0%) 0.60% +0.598 pp 0.08% +0.084 pp USD5.80 +0.0% 1 qtrs NEW
12 683 CAPITAL MANAGEMENT, LLC 80.1K +80.1K (+100.0%) 464.7K +464.7K (+100.0%) 0.48% +0.479 pp 0.02% +0.020 pp USD5.80 +0.0% 1 qtrs NEW
13 BLACKROCK, INC. 79.1K +9.2K (+13.1%) 459.0K +60.3K (+15.1%) 0.47% +0.055 pp 0.00% +0.000 pp USD6.28 -7.6% 6 qtrs —
14 STATE STREET CORP 69.5K +21.4K (+44.5%) 403.2K +129.0K (+47.0%) 0.42% +0.128 pp 0.00% +0.000 pp USD8.27 -29.9% 8 qtrs —
15 RENAISSANCE TECHNOLOGIES LLC 66.9K +32.1K (+92.2%) 388.0K +189.7K (+95.6%) 0.40% +0.192 pp 0.00% +0.000 pp USD5.89 -1.5% 7 qtrs —
16 SQUAREPOINT OPS LLC 65.2K +65.2K (+100.0%) 377.9K +377.9K (+100.0%) 0.39% +0.389 pp 0.00% +0.000 pp USD5.80 +0.0% 1 qtrs NEW
17 POINT72 ASSET MANAGEMENT, L.P. 61.6K +61.6K (+100.0%) 357.2K +357.2K (+100.0%) 0.37% +0.368 pp 0.00% +0.000 pp USD5.80 +0.0% 1 qtrs NEW
18 MORGAN STANLEY 53.4K +51.8K (+3,398.8%) 309.5K +300.8K (+3,459.9%) 0.32% +0.310 pp 0.00% +0.000 pp USD5.80 +0.0% 11 qtrs —
19 PRELUDE CAPITAL MANAGEMENT, LLC 52.3K +16.5K (+46.1%) 303.2K +99.3K (+48.7%) 0.31% +0.099 pp 0.02% +0.006 pp USD4.46 +30.0% 10 qtrs —
20 NORTHERN TRUST CORP 40.4K +8.1K (+25.1%) 234.4K +50.2K (+27.2%) 0.24% +0.048 pp 0.00% +0.000 pp USD7.17 -19.1% 9 qtrs —
21 BANK OF AMERICA CORP /DE/ 39.8K +39.6K (+18,404.2%) 230.7K +229.5K (+18,721.1%) 0.24% +0.237 pp 0.00% +0.000 pp USD5.81 -0.2% 11 qtrs —
22 LONG CORRIDOR ASSET MANAGEMENT LTD 38.8K +38.8K (+100.0%) 224.8K +224.8K (+100.0%) 0.23% +0.232 pp 0.01% +0.015 pp USD5.80 +0.0% 1 qtrs NEW
23 WALLEYE CAPITAL LLC 37.1K +37.1K (+100.0%) 215.0K +215.0K (+100.0%) 0.22% +0.222 pp 0.00% +0.001 pp USD5.80 +0.0% 1 qtrs NEW
24 WESTWOOD HOLDINGS GROUP INC 36.7K +36.7K (+100.0%) 212.6K +212.6K (+100.0%) 0.22% +0.219 pp 0.00% +0.002 pp USD5.80 +0.0% 1 qtrs NEW
25 UBS GROUP AG 35.0K +21.7K (+163.5%) 203.2K +127.4K (+168.1%) 0.21% +0.130 pp 0.00% +0.000 pp USD5.77 +0.5% 13 qtrs —
26 OMERS ADMINISTRATION CORP 34.5K +34.5K (+100.0%) 200.1K +200.1K (+100.0%) 0.21% +0.206 pp 0.00% +0.001 pp USD5.80 +0.0% 1 qtrs NEW
27 JUMP FINANCIAL, LLC 34.2K +34.2K (+100.0%) 198.4K +198.4K (+100.0%) 0.20% +0.204 pp 0.00% +0.002 pp USD5.80 +0.0% 1 qtrs NEW
28 JANE STREET GROUP, LLC 33.8K +33.8K (+100.0%) 196.2K +196.2K (+100.0%) 0.20% +0.202 pp 0.00% +0.000 pp USD5.80 +0.0% 5 qtrs —
29 XTX TOPCO LTD 33.1K +33.1K (+100.0%) 191.8K +191.8K (+100.0%) 0.20% +0.198 pp 0.01% +0.005 pp USD5.80 +0.0% 1 qtrs NEW
30 DIMENSIONAL FUND ADVISORS LP 31.4K +11.6K (+58.9%) 182.3K +69.5K (+61.7%) 0.19% +0.070 pp 0.00% +0.000 pp USD5.77 +0.5% 3 qtrs —
31 ROYAL BANK OF CANADA 27.4K -7.9K (-22.5%) 159.0K -43.0K (-21.3%) 0.16% -0.048 pp 0.00% +0.000 pp USD7.15 -18.9% 11 qtrs —
32 GHP INVESTMENT ADVISORS, INC. 26.2K +— (+0.0%) 151.8K +2.6K (+1.8%) 0.16% 0.000 pp 0.01% +0.000 pp USD6.45 -10.1% 6 qtrs —
33 TREXQUANT INVESTMENT LP 25.0K +25.0K (+100.0%) 145.0K +145.0K (+100.0%) 0.15% +0.149 pp 0.00% +0.001 pp USD5.80 +0.0% 1 qtrs NEW
34 CETERA INVESTMENT ADVISERS 22.0K +22.0K (+100.0%) 127.6K +127.6K (+100.0%) 0.13% +0.132 pp 0.00% +0.000 pp USD5.80 +0.0% 1 qtrs NEW
35 MILLENNIUM MANAGEMENT LLC 20.8K +20.8K (+100.0%) 120.9K +120.9K (+100.0%) 0.12% +0.125 pp 0.00% +0.000 pp USD5.80 +0.0% 1 qtrs NEW
36 GSA CAPITAL PARTNERS LLP 20.7K +20.7K (+100.0%) 120.0K +120.0K (+100.0%) 0.12% +0.124 pp 0.01% +0.010 pp USD5.80 +0.0% 1 qtrs NEW
37 NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 20.6K +— (+0.0%) 119.6K +2.1K (+1.8%) 0.12% 0.000 pp 0.00% +0.000 pp USD5.75 +0.9% 3 qtrs —
38 QUBE RESEARCH & TECHNOLOGIES LTD 20.5K +20.5K (+100.0%) 119.0K +119.0K (+100.0%) 0.12% +0.123 pp 0.00% +0.000 pp USD5.80 +0.0% 1 qtrs NEW
39 CITADEL ADVISORS LLC 20.1K -45.2K (-69.2%) 116.5K -255.4K (-68.7%) 0.12% -0.270 pp 0.00% +0.000 pp USD6.11 -5.1% 4 qtrs —
40 LANTERN WEALTH ADVISORS, LLC 17.8K +6.3K (+54.0%) 103.4K +37.4K (+56.7%) 0.11% +0.037 pp 0.05% +0.020 pp USD5.74 +1.0% 2 qtrs —
41 OPPENHEIMER & CO INC 14.0K +14.0K (+100.0%) 81.2K +81.2K (+100.0%) 0.08% +0.084 pp 0.00% +0.001 pp USD5.80 +0.0% 1 qtrs NEW
42 LIGHTHOUSE INVESTMENT PARTNERS, LLC 11.8K +11.8K (+100.0%) 68.2K +68.2K (+100.0%) 0.07% +0.070 pp 0.00% +0.002 pp USD5.80 +0.0% 1 qtrs NEW
43 OCCUDO QUANTITATIVE STRATEGIES LP 11.4K +11.4K (+100.0%) 65.9K +65.9K (+100.0%) 0.07% +0.068 pp 0.00% +0.004 pp USD5.80 +0.0% 1 qtrs NEW
44 RAYMOND JAMES FINANCIAL INC 11.0K +11.0K (+100.0%) 63.7K +63.7K (+100.0%) 0.07% +0.066 pp 0.00% +0.000 pp USD5.80 +0.0% 3 qtrs —
45 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 10.0K +— (+0.0%) 58.0K +1.0K (+1.8%) 0.06% +0.000 pp 0.00% +0.000 pp USD6.47 -10.4% 4 qtrs —
46 CIBC PRIVATE WEALTH GROUP, LLC 8.1K +8.1K (+100.0%) 47.0K +47.0K (+100.0%) 0.05% +0.048 pp 0.00% +0.000 pp USD5.80 +0.0% 1 qtrs NEW
47 JONES FINANCIAL COMPANIES LLLP 5.1K +5.1K (+100.0%) 29.4K +29.4K (+100.0%) 0.03% +0.030 pp 0.00% +0.000 pp USD5.80 +0.0% 1 qtrs NEW
48 JPMORGAN CHASE & CO 5.0K +— (+0.0%) 29.0K +500.0 (+1.8%) 0.03% +0.000 pp 0.00% +0.000 pp USD5.70 +1.8% 2 qtrs —
49 STATE OF WYOMING 4.2K +924.0 (+28.3%) 24.3K +5.7K (+30.6%) 0.03% +0.006 pp 0.00% +0.001 pp USD5.76 +0.7% 3 qtrs —
50 IFP ADVISORS, INC 3.8K +3.8K (+100.0%) 22.0K +22.0K (+100.0%) 0.02% +0.023 pp 0.00% +0.001 pp USD5.80 +0.0% 1 qtrs NEW
51 BFSG, LLC 2.7K +2.7K (+100.0%) 15.6K +15.6K (+100.0%) 0.02% +0.016 pp 0.00% +0.002 pp USD5.80 +0.0% 1 qtrs NEW
52 ROCKEFELLER CAPITAL MANAGEMENT L.P. 1.5K +1.0K (+200.0%) 8.7K +5.9K (+205.3%) 0.01% +0.006 pp 0.00% +0.000 pp USD5.77 +0.5% 2 qtrs —
53 ALLWORTH FINANCIAL LP 1.0K +— (+0.0%) 5.8K +100.0 (+1.8%) 0.01% +0.000 pp 0.00% +0.000 pp USD5.75 +0.9% 3 qtrs —
54 SBI SECURITIES CO., LTD. 921.00 -1.0 (-0.1%) 5.3K +87.0 (+1.7%) 0.01% +0.000 pp 0.00% +0.000 pp USD5.85 -0.9% 5 qtrs —
55 STEWARD PARTNERS INVESTMENT ADVISORY, LLC 500.00 +— (+0.0%) 2.9K +50.0 (+1.8%) 0.00% +0.000 pp 0.00% +0.000 pp USD5.73 +1.2% 5 qtrs —
56 HARBOUR INVESTMENTS, INC. 172.00 +40.0 (+30.3%) 998.00 +246.0 (+32.7%) 0.00% +0.000 pp 0.00% +0.000 pp USD5.72 +1.4% 2 qtrs —
57 TRIUMPH CAPITAL MANAGEMENT 50.00 +— (+0.0%) 290.00 +5.0 (+1.8%) 0.00% +0.000 pp 0.00% +0.000 pp USD5.70 +1.8% 2 qtrs —
58 CITIGROUP INC 1.00 +1.0 (+100.0%) 6.00 +6.0 (+100.0%) 0.00% +0.000 pp 0.00% +0.000 pp USD5.00 +16.0% 1 qtrs NEW
59 DAUNTLESS INVESTMENT GROUP, LLC — -153.0K (-100.0%) — -872.2K (-100.0%) 0.00% -0.915 pp 0.00% -0.545 pp USD— 4 qtrs SOLD
60 ADVISOR GROUP HOLDINGS, INC. — -1.5K (-100.0%) — -9.6K (-100.0%) 0.00% -0.009 pp 0.00% +0.000 pp USD— 7 qtrs SOLD
61 QUADRATURE CAPITAL LTD — -19.9K (-100.0%) — -113.8K (-100.0%) 0.00% -0.119 pp 0.00% -0.001 pp USD— 2 qtrs SOLD
62 EVERSOURCE WEALTH ADVISORS, LLC — -76.0 (-100.0%) — -433.0 (-100.0%) 0.00% -0.001 pp 0.00% +0.000 pp USD— 3 qtrs SOLD
63 TOWER RESEARCH CAPITAL LLC (TRC) — -988.0 (-100.0%) — -5.6K (-100.0%) 0.00% -0.006 pp 0.00% 0.000 pp USD— 10 qtrs SOLD
Ownership breakdown by holder

ETF Ownership

Top ETFs holding this stock Held by 18 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares Micro-Cap ETF IWC 0.02% 346.7K 0.60%
2 Dimensional - US Small Cap ETF DFAS 0.00% 397.7K 0.26%
3 U.S. Micro Cap Portfolio ETF DFMC 0.00% 199.6K 0.43%
4 Vanguard Extended Market ETF VXF 0.00% 1.04M 0.05%
5 Dimensional - US Core Equity 1 ETF DCOR 0.00% 15.0K 0.14%
6 Avantis U.S. Small Cap Equity ETF AVSC 0.00% 4.6K 0.25%
7 Vanguard U.S. Total Market Shares Index ETF VTS.AX 0.00% 6.1K 0.03%
8 Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO 0.00% 1.2K 0.17%
9 Vanguard U.S. Total Market Index ETF VUN.TO 0.00% 16.9K 0.17%
10 Vanguard Total Stock Market ETF VTI 0.00% 2.88M 0.03%

Insider Activity

Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
10.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+10,000
Insider buys vs sells (history) From To
Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2026-04-09 Pavao Mark H Director A-Award A Stock Option (right to buy) 10,000 4.53 45.3K 10,000 D ↗
2026-04-01 Pavao Mark H — — — — 0 0.00 — 0 — ↗
2026-01-22 Swaminathan Arun Director / Officer A-Award A Stock Option (right to buy) 293,983 4.73 1.39M 293,983 D ↗
2026-01-22 SNYDER DAVID S Officer A-Award A Stock Option (right to buy) 140,041 4.73 662.4K 140,041 D ↗
2026-01-22 Grossman Fred Officer A-Award A Stock Option (right to buy) 140,041 4.73 662.4K 140,041 D ↗
2026-01-22 Berman Howard Director / Officer A-Award A Stock Option (right to buy) 15,257 4.73 72.2K 15,257 D ↗
2026-01-02 Weinand Dieter Director A-Award A Stock Option (right to buy) 10,000 5.65 56.5K 10,000 D ↗
2026-01-02 Villalobos Anabella Director A-Award A Stock Option (right to buy) 10,000 5.65 56.5K 10,000 D ↗
2026-01-02 ROSS WILBUR L JR Director A-Award A Stock Option (right to buy) 10,000 5.65 56.5K 10,000 D ↗
2026-01-02 Lee Ann Director A-Award A Stock Option (right to buy) 10,000 5.65 56.5K 10,000 D ↗
2026-01-02 GOLDSTEIN DOV A MD Director A-Award A Stock Option (right to buy) 10,000 5.65 56.5K 10,000 D ↗
2025-08-18 GOLDSTEIN DOV A MD Director M-Exempt A Common Stock, par value $0.0001 per share 17,557 1.09 19.1K 27,557 D ↗
2025-02-25 Weinand Dieter Director A-Award A Stock Option (right to buy) 5,000 5.97 29.9K 5,000 D ↗
2025-02-25 Villalobos Anabella Director A-Award A Stock Option (right to buy) 5,000 5.97 29.9K 5,000 D ↗
2025-02-25 ROSS WILBUR L JR Director A-Award A Stock Option (right to buy) 5,000 5.97 29.9K 5,000 D ↗
2025-02-25 Lee Ann Director A-Award A Stock Option (right to buy) 5,000 5.97 29.9K 5,000 D ↗
2025-02-25 GOLDSTEIN DOV A MD Director A-Award A Stock Option (right to buy) 5,000 5.97 29.9K 5,000 D ↗
2025-01-09 Swaminathan Arun Director / Officer A-Award A Stock Option (right to buy) 240,964 6.07 1.46M 240,964 D ↗
2025-01-09 SNYDER DAVID S Officer A-Award A Stock Option (right to buy) 140,562 6.07 853.2K 140,562 D ↗
2025-01-09 Grossman Fred Officer A-Award A Stock Option (right to buy) 140,562 6.07 853.2K 140,562 D ↗
2025-01-09 Berman Howard Director A-Award A Stock Option (right to buy) 150,602 6.07 914.2K 150,602 D ↗
2025-01-01 Weinand Dieter Director A-Award A Stock Option (right to buy) 5,000 5.73 28.7K 5,000 D ↗
2025-01-01 Villalobos Anabella Director A-Award A Stock Option (right to buy) 5,000 5.73 28.7K 5,000 D ↗
2025-01-01 ROSS WILBUR L JR Director A-Award A Stock Option (right to buy) 5,000 5.73 28.7K 5,000 D ↗
2025-01-01 Lee Ann Director A-Award A Stock Option (right to buy) 5,000 5.73 28.7K 5,000 D ↗
2025-01-01 GOLDSTEIN DOV A MD Director A-Award A Stock Option (right to buy) 5,000 5.73 28.7K 5,000 D ↗
2024-11-14 SNYDER DAVID S Officer P-Purchase A Common Stock, par value $0.0001 per share 1,800 7.19 12.9K 8,800 D ↗
2024-11-13 Swaminathan Arun Director / Officer P-Purchase A Common Stock, par value $0.0001 per share 5,000 7.36 36.8K 10,000 D ↗
2024-11-11 Swaminathan Arun Director / Officer P-Purchase A Common Stock, par value $0.0001 per share 5,000 7.34 36.7K 5,000 D ↗
2024-11-11 Grossman Fred Officer P-Purchase A Common Stock, par value $0.0001 per share 2,710 7.37 20.0K 2,710 D ↗
2024-08-19 Swaminathan Arun Director — D Stock Option (right to buy) 115,000 4.05 465.8K 0 — ↗
2024-06-03 SNYDER DAVID S Officer A-Award A Stock Option (right to buy) 70,596 8.15 575.4K 70,596 — ↗
2024-06-03 Grossman Fred Officer A-Award A Stock Option (right to buy) 70,596 8.15 575.4K 70,596 — ↗
2024-06-03 Berman Howard Director / Officer A-Award A Stock Option (right to buy) 163,663 8.15 1.33M 163,663 — ↗
2024-01-31 SNYDER DAVID S Officer A-Award A Stock Option (right to buy) 81,819 5.90 482.7K 81,819 — ↗
2024-01-31 Grossman Fred Officer A-Award A Stock Option (right to buy) 74,069 5.90 437.0K 74,069 — ↗
2024-01-31 Berman Howard Director / Officer A-Award A Stock Option (right to buy) 189,680 5.90 1.12M 189,680 — ↗
2024-01-02 ROSS WILBUR L JR Director A-Award A Stock Option (right to buy) 10,000 6.97 69.7K 10,000 — ↗
2024-01-01 Weinand Dieter Director A-Award A Stock Option (right to buy) 5,000 7.41 37.1K 5,000 — ↗
2024-01-01 Villalobos Anabella Director A-Award A Stock Option (right to buy) 5,000 7.41 37.1K 5,000 — ↗
2024-01-01 Lee Ann Director A-Award A Stock Option (right to buy) 5,000 7.41 37.1K 5,000 — ↗
2024-01-01 Garren Hideki Director A-Award A Stock Option (right to buy) 5,000 7.41 37.1K 5,000 — ↗
2024-01-01 GOLDSTEIN DOV A MD Director A-Award A Stock Option (right to buy) 5,000 7.41 37.1K 5,000 — ↗
2023-12-19 ROSS WILBUR L JR Director — I Common Stock, par value $0.0001 per share 0 0.00 — 165,016 — ↗
2023-08-22 Lee Ann Director P-Purchase A Common Stock, par value $0.0001 per share 1,000 3.62 3.6K 17,479 — ↗
2023-08-18 Weinand Dieter Director A-Award A Stock Option (right to buy) 10,000 3.43 34.3K 10,000 — ↗
2023-07-17 Grossman Fred Officer — — — 0 0.00 — 0 — ↗
2023-02-27 SNYDER DAVID S Officer A-Award A Stock Option (right to buy) 115,000 3.85 442.8K 115,000 — ↗
2023-02-27 Hepner Adrian Officer A-Award A Stock Option (right to buy) 115,000 3.85 442.8K 115,000 — ↗
2023-02-27 Berman Howard Director / Officer A-Award A Stock Option (right to buy) 165,000 3.85 635.3K 165,000 — ↗
2023-01-03 Villalobos Anabella Director P-Purchase A Common Stock, par value $0.0001 per share 10,000 0.00 — 10,000 — ↗
2023-01-03 SNYDER DAVID S Officer P-Purchase A Common Stock, par value $0.0001 per share 7,000 0.00 — 7,000 — ↗
2023-01-03 Lee Ann Director C-Conversion A Common Stock, par value $0.0001 per share 6,479 4.00 25.9K 16,479 — ↗
2023-01-03 Hepner Adrian Officer P-Purchase A Warrant to Purchase Common Stock 5,000 0.00 — 5,000 — ↗
2023-01-03 Garren Hideki Director P-Purchase A Common Stock, par value $0.0001 per share 2,000 0.00 — 2,000 — ↗
2023-01-03 GOLDSTEIN DOV A MD Director P-Purchase A Common Stock, par value $0.0001 per share 10,000 0.00 — 10,000 — ↗
2023-01-03 Berman Howard Director / Officer / 10% Owner — — — 0 0.00 — 0 — ↗
2022-12-28 SNYDER DAVID S Officer — D Stock Option (right to buy) 87,788 3.47 304.6K — — ↗
2022-12-28 Lee Ann Director — D 6% Convertible Note 6,445 4.00 25.8K — — ↗
2022-12-28 Bertex LLC Director — D Common Stock 0 0.00 — 939,338 — ↗
2022-12-28 Berman Howard Officer — I Common Stock, par value $0.0001 per share 0 0.00 — 939,338 — ↗
2022-11-01 Hepner Adrian Officer — D Stock Option (right to buy) 43,894 3.47 152.3K — — ↗
2022-05-01 Garren Hideki Director — D Stock Option (right to buy) 17,557 1.09 19.1K — — ↗
2021-07-01 Villalobos Anabella Director — D Stock Option (right to buy) 17,557 1.09 19.1K — — ↗
2021-04-01 GOLDSTEIN DOV A MD Director — D Stock Option (right to buy) 17,557 1.09 19.1K — — ↗

Executive team

Top executives
EBIT / Employee
-25.3K
Shares Outstanding
16.73M

Executive compensation

Executive compensation (annual)
# Year ⇅ Executive ⇅ Salary ⇅ Bonus Stock award ⇅ Option award Incentive Other Total ⇅ % Stock-
based ⇅		 Filing
1 2024 Howard Berman Former Chief Executive Officer, Current Executive Chairman of the Board 553.3K 276.7K — 1.85M — — 2.68M 69.03% ↗
2 2024 Fred Grossman President, Chief Medical Officer 479.0K 191.6K — 1.22M — — 1.89M 64.56% ↗
3 2024 Arun Swaminathan Chief Executive Officer, Director 441.7K 185.4K — 870.1K — — 1.50M 58.12% ↗
4 2024 David Snyder Chief Financial Officer and Chief Operating Officer 425.0K 170.0K — 870.1K — — 1.47M 59.39% ↗
5 2023 Howard Berman Chief Executive Officer 580.0K 253.8K — 483.5K — — 1.32M 36.70% ↗
6 2023 Howard Berman Former Chief Executive Officer, Current Executive Chairman of the Board 580.0K 253.8K — 483.5K — — 1.32M 36.70% ↗
7 2023 David Snyder Chief Financial Officer and Chief Operating Officer 425.0K 185.9K — 337.0K — — 947.9K 35.55% ↗
8 2023 Adrian Hepner Former President, Chief Medical Officer 285.2K — — 337.0K — — 622.2K 54.16% ↗
9 2023 Fred Grossman President, Chief Medical Officer 227.0K 113.5K — 252.0K — — 592.5K 42.53% ↗
10 2022 Adrian Hepner President, Chief Medical Officer 425.0K 194.8K — 106.3K — — 772.5K 13.75% ↗
11 2022 Adrian Hepner Former President, Chief Medical Officer 425.0K 194.8K — 106.7K — — 726.5K 14.68% ↗
12 2022 David Snyder Chief Financial Officer and Chief Operating Officer 279.8K 111.9K — 216.8K — — 608.5K 35.63% ↗
13 2022 Howard Berman Chief Executive Officer 412.5K 185.6K — — — — 598.1K 0.00% ↗
14 2021 Howard Berman Chief Executive Officer 300.0K 90.0K — — — — 390.0K 0.00% ↗
15 2021 Adrian Hepner President, Chief Medical Officer 70.8K — — 56.0K — — 126.9K 44.16% ↗
CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2025-05-16 DEFA14A ↗
2025-05-16 DEF 14A ↗
2024-03-29 DEFA14A ↗
2024-03-28 DEFA14A ↗

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2026-04-09 4 ↗
2026-04-09 3 ↗
2026-04-02 8-K ↗
2026-03-20 EFFECT ↗
2026-03-20 424B3 ↗
2026-03-16 S-3 ↗
2026-03-16 8-K ↗
2026-03-16 10-K ↗
2026-03-12 SC 13G ↗
2026-01-30 SC 13G/A ↗

Executive team

NameTitleCompensationGender
Arun Swaminathan Chief Executive Officer & Director 941.9K —
Fred Grossman FAPA President & Chief Medical Officer 787.1K —
Howard Berman Co-Founder & Executive Chair 753.5K —
David S. Snyder Chief Financial Officer & Chief Operating Officer 698.4K male
Aaron Thome Head of Neuroinflammation Platform — male
Karen King Senior Vice President of Program Management & Clinical Operations — female
Michelle Frazier Senior Vice President of Regulatory — —
ESG Rating
B
BIOTECHNOLOGY
Rank: 551 out of 710
2025
E (Environmental)
54.4 / 56.3
Company / Sector avg.
S (Social)
62.4 / 62.4
Company / Sector avg.
G (Governance)
62.1 / 60.9
Company / Sector avg.
ESG Total
59.7 / 59.9
Company / Sector avg.
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology